STEMI Treatment Optimization by Ischemic Postconditioning and IVUS Guidance

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorThomas Engstrom

About this trial

The purpose of is study is to investigate whether ischemic postconditioning (iPOST) and intravascular ultrasound-guided (IVUS) percutaneous coronary intervention (PCI) improve the clinical outcome of patients with ST-segment elevation myocardial infarction treated with primary PCI.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years

Acute onset of chest pain with <12 hours duration

STEMI as characterized by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or 1 mV ST-segment elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior AMI.

Disqualifiers

None

Trial design

Design model

Factorial

Treatments tested in this trial

  • PCI + Ischemic conditioning

    Procedure/Surgery

    IPOST is repeated for 4 cycles (60 sec obstruction followed by 60 sec perfusion each) and followed by stent implantation with a 1.1/1.0 ratio of stent diameter/reference vessel diameter and a stent length sufficient to cover the entire lesion from healthy to healthy area of the vessel. During the first cycle of re-occlusion of full vessel occlusion is secured by a small injection of contrast.

  • Stent with ultrasound

    Procedure/Surgery

    IVUS catheters are to be advanced at least 20 mm distal to the culprit lesion. After administration of intracoronary nitroglycerine, an IVUS-pullback is to be performed at 0.5mm/second using a commercially available imaging system. Stent size and landing zones are decided based on the IVUS.

Treatment groups

2,500 Participants
are divided into 4 treatment groups
Group A: PCI standardActive comparator 1 intervention
Group B: PCI standard + ischemic conditioningExperimental treatment 1 intervention
Group C: Stent with ultrasoundExperimental treatment 1 intervention
Group D: Stent without ultrasoundActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

iPOST

Number of participants that experience all-cause mortality or hospitalization for heart failure

Time frame
Until expected number of events are adjudicated up til 3 years
2

iSTEMI (IVUS)

Number of participants that experience all-cause mortality, unplanned ischemia-driven revascularization and new myocardial infarction

Time frame
Until expected number of events are adjudicated up til 3 years

Secondary outcomes

1

iSTEMI (IVUS)

Target vessel failure (cardiac mortality, unplanned ischemia driven target vessel revascularization or target vessel myocardial infarction

Time frame
Until expected number of events are adjudicated 3 years
2

iSTEMI (IVUS)

Individual components of the primary endpoint

Time frame
Until expected number of events are adjudicated 3 years
3

iSTEMI (IVUS)

Cardiac mortality

Time frame
Until expected number of events are adjudicated 3 years
4

iSTEMI (IVUS)

Unplanned ischemia driven target vessel revascularization

Time frame
Until expected number of events are adjudicated 3 years

Other outcomes

1

iSTEMI (IVUS)

Hospitalization for heart failure

Time frame
Until expected number of events are adjudicated 3 years
2

iSTEMI (IVUS)

Stroke

Time frame
Until expected number of events are adjudicated 3 years
3

iSTEMI (IVUS)

Bleeding

Time frame
Until expected number of events are adjudicated 3 years
4

iSTEMI (IVUS)

Quality of life

Time frame
1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Thomas Engstrom

Lead sponsor

Rigshospitalet, Denmark

Sponsor institution